Simplify Drug Labelling to Show Benefits Clearly

Darrow JJ - Nature

  • Regulation and Clinical Evidence

Summary:

FDA drug labeling fails to clearly communicate how well drugs actually work, as though detailed safety warnings are required, there is no mandate to include understandable efficacy information. Drug labels should include meaningful, patient-relevant benefit metrics to help physicians and patients make more informed treatment decisions.

VIEW SOURCE

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway

Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy

  • Price, Value, and Access
  • Regulation and Clinical Evidence
Talk bubble graphics representing commentary and opinion.

Politics and the Patient Encounter, in Dire Times

Avorn J - MedPage Today

  • Regulation and Clinical Evidence